In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Ferinject (Vifor Pharma); Injectafer (American Reagent)
- INDICATIONS: Iron deficiency anemia in adult patients
- CLASS: Iron supplement
- HALF-LIFE: 7–12 hours
- FDA APPROVAL DATE: 07/25/2013
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of
which have been life-threatening and fatal, have been reported in patients receiving
ferric carboxymaltose injection. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ferric carboxymaltose (injection) in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
